LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)

Disseminated on behalf of Nevada Organic Phosphate Inc., may include paid advertisements.

The QualityStocks Daily Newsletter would like to spotlight LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT).

• LIXTE Biotechnology Holdings and the company’s subsidiary, Liora Technologies, both develop products that aim to improve outcomes for cancer patients
• Specifically, Liora’s Linac for Image Guided Hadron Therapy (“LiGHT”) System and LIXTE’s LB-100 work together to fight cancer
• As a result, the companies are building a new cancer care ecosystem that hopes to boost the effectiveness of treatments, while also help them be more accessible for a wider range of patients

Recently, LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) , a clinical-stage pharmaceutical company, acquired Liora Technologies, a company that is aiming to transform cancer care with innovative compact proton therapy.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is a clinical-stage pharmaceutical company developing differentiated cancer therapies built around a novel biological target. Rather than introducing standalone treatments, the company is focused on advancing a first-in-class approach designed to enhance the effectiveness of established cancer therapies, addressing persistent challenges that continue to limit outcomes in oncology.

LIXTE’s work centers on improving how chemotherapy and immunotherapy perform in difficult-to-treat cancers with significant unmet medical need. By translating a distinct scientific concept into therapies that can be integrated into existing treatment frameworks, the company aims to expand the reach and impact of current standards of care without requiring wholesale changes to clinical practice.

Alongside internal development, LIXTE has pursued selective strategic actions that extend its capabilities beyond drug development, supporting its evolution into a platform-oriented oncology company spanning both pharmaceutical and technology-driven approaches.

The company is headquartered in Boca Raton, Florida.

Portfolio

LB-100 (PP2A Inhibitor Platform)

LIXTE’s lead clinical candidate, LB-100, is a proprietary small-molecule inhibitor of protein phosphatase 2A (PP2A) designed to enhance the activity of chemotherapy and immunotherapy. The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies. LB-100 is currently being evaluated in multiple clinical programs targeting solid tumors with limited treatment options.

Ongoing trials include combinations of LB-100 with immunotherapy in ovarian clear cell carcinoma and metastatic MSI-low colon cancer, as well as combination therapy with chemotherapy in advanced soft tissue sarcoma. These studies are being conducted in collaboration with leading academic cancer centers and industry partners, reflecting LIXTE’s emphasis on externally validated clinical execution.

Radiotherapy Platform Expansion (Liora Technologies)

In November 2025, LIXTE expanded beyond pharmaceuticals with the acquisition of Liora Technologies Europe Ltd., adding an electronically controlled proton therapy platform known as the LiGHT System. This acquisition established LIXTE’s entry into radiotherapy, complementing its drug development activities and creating optionality for future recurring revenue models tied to jointly operated treatment centers.

Market Opportunity

LIXTE is targeting cancers where existing therapies show limited durability due to resistance, toxicity constraints, or suboptimal patient response. Chemotherapy and immunotherapy are widely applicable across tumor types but remain constrained by these factors, creating an opportunity for approaches that improve efficacy without proportionally increasing toxicity.

The company’s clinical programs focus on ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, indications characterized by high unmet need and limited effective treatment options. Rather than reshaping oncology care, LIXTE is developing LB-100 to augment existing therapies, an approach that could support wider clinical use within established treatment pathways.

Leadership Team

Geordan Pursglove, Chairman, President and Chief Executive Officer, is an accomplished executive and entrepreneur with more than a decade of experience spanning mergers and acquisitions, capital markets, strategic growth initiatives, and operational leadership across both public and private companies. His background includes leadership roles across technology, logistics, customer experience, sports, and marketing, with a focus on scaling organizations, raising capital, and executing transformative strategies.

Bas van der Baan, Chief Scientific Officer, has more than 20 years of experience in biotechnology with a concentration in oncology and diagnostics. He previously served as Chief Clinical and Business Development Officer at Agendia, where he played a key role in initiating and executing clinical trials that supported the commercialization of precision molecular oncology diagnostics in both the U.S. and Europe.

Peter Stazzone, Chief Financial Officer, brings over two decades of financial management experience across publicly traded and privately held companies. His background includes leading capital raises, mergers and acquisitions, financial controls, and public company reporting, with prior CFO roles at companies including Beyond Commerce, Strainz, and Voice Telecom.

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), closed Monday's trading session at $2.51, up 2.8689%, on 50,816 volume. The average volume for the last 3 months is 47,805 and the stock's 52-week low/high is $0.64/$6.26.

Recent News

• LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances Lead Compound in Tumor Immunogenicity Research
• TinyGemsBreaks - LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline
• Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

NRx Pharmaceuticals Inc. (NASDAQ: NRXP)

The QualityStocks Daily Newsletter would like to spotlight NRx Pharmaceuticals Inc. (NASDAQ: NRXP).

NRx Pharmaceuticals (NASDAQ: NRXP) announced that its subsidiary HOPE Therapeutics has opened a new clinic in Palm Beach, Florida, focused on treating depression and post-traumatic stress disorder through an interventional psychiatry approach that includes ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy and physician-led psychotherapy. The facility expands HOPE’s growing network of clinics and builds on a nationwide partnership with neurocare AG to bring non-invasive neuroplastic therapies to patients. Peer-reviewed publications cited by the company report an 87% clinical response rate in treatment-resistant depression using short-term treatment protocols, while pilot programs incorporating hyperbaric oxygen therapy have shown a 90% return-to-function rate among patients with depression and PTSD.

To view the full press release, visit https://ibn.fm/q4bu5

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, with a particular emphasis on conditions characterized by acute suicidality. The company is leveraging its proprietary NMDA receptor modulation platform to address significant unmet medical needs in suicidal depression, bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD).

With a commitment to advancing life-saving treatments, NRx is developing novel therapeutics aimed at providing safer and more effective alternatives to current treatment options. Its lead investigational drug, NRX-101, is positioned to be the first FDA-approved oral therapy for suicidal bipolar depression. Additionally, the company is working to bring NRX-100 (intravenous ketamine) to market as an approved treatment for acute suicidal depression, a condition for which existing treatments remain limited.

By integrating cutting-edge science with a patient-focused mission, NRx aims to transform the standard of care for individuals suffering from severe psychiatric and neurological conditions.

NRx has also established HOPE Therapeutics, a subsidiary focused on delivering interventional psychiatric care through a nationwide clinic network. HOPE Therapeutics aims to become the first coordinated system of care for suicidal depression and PTSD, combining ketamine, Transcranial Magnetic Stimulation (TMS), digital therapeutics, and other precision psychiatry tools in a supervised clinical environment.

NRx is headquartered in Wilmington, Delaware. HOPE is headquartered in Miami, Florida.

Product Portfolio

NRx Pharmaceuticals’ pipeline includes multiple late-stage therapeutic candidates targeting psychiatric and neurological disorders:

• NRX-100: A preservative free intravenous ketamine formulation under development for acute suicidal depression, backed by strong clinical trial data and Fast Track designation from the FDA.
• NRX-101: An oral therapy with a dual mechanism targeting NMDA and 5-HT2A receptors, designed for patients with suicidal treatment-resistant bipolar depression. The drug has received Breakthrough Therapy designation from the FDA.
• Expanded Research: The company is further evaluating NRX-101 as a potential non-opioid treatment for chronic pain and a therapy for complicated urinary tract infections.

NRx’s therapeutic pipeline is designed to address conditions with limited or no treatment options, with the potential to improve patient outcomes and expand the standard of care.

HOPE Therapeutics

HOPE Therapeutics, a wholly owned subsidiary of NRx Pharmaceuticals, is establishing a national network of psychiatrist-led clinics focused on suicidal depression and PTSD. Its care model integrates preservative-free ketamine, TMS, digital therapeutics, and supervised psychiatric support to deliver rapid, measurable outcomes.

The company is targeting more than 30 clinic acquisitions by year-end 2025. Recent agreements include the acquisition of Dura Medical and a letter of intent with Neurospa TMS, strengthening HOPE’s foundation in interventional psychiatry. In April, HOPE also secured a term sheet for strategic investment from a global medical device manufacturer.

With ketamine sales already underway under a 503B license, HOPE projects $100 million in annual revenue and profitability by year-end 2025. Positioned as a standalone care delivery company, HOPE offers NRx a potential future spinout opportunity to unlock additional shareholder value.

Market Opportunity

The need for innovative treatments in mental health and pain management is substantial. Suicide is a leading cause of death in the United States, claiming nearly 50,000 lives each year, with over 12 million adults seriously considering suicide annually, according to the CDC.

Suicidal depression, a distinct and life-threatening condition, affects approximately 3.5 million Americans. Despite this prevalence, the only approved intervention remains electroconvulsive therapy (ECT), a treatment with significant side effects and limited access. NRx aims to address this urgent gap with NRX-100, a preservative-free intravenous ketamine formulation being developed as the first FDA-approved treatment specifically for suicidal depression.

Additionally, approximately 7 million Americans suffer from bipolar depression, a condition where nearly half of patients will attempt suicide during their lifetime and one in five may die by suicide. NRX-101, NRx’s oral drug candidate, targets this critical unmet need as a potential first-in-class therapy specifically for bipolar depression.

Beyond mood disorders, chronic pain affects over 50 million individuals in the U.S., and PTSD impacts more than 12 million people—conditions for which few non-opioid, fast-acting treatments are available. By addressing these high-risk, underserved populations, NRx Pharmaceuticals is positioned to enter multiple billion-dollar markets and reshape the standard of care for severe psychiatric and neurological illnesses.

Leadership Team

Jonathan C. Javitt, Founder, Chairman & Chief Executive Officer or NRx, and Co-CEO of HOPE, brings four decades of experience in pharmaceutical and medical device development. He has led blockbuster drug and device programs at major companies, including Allergan, Merck, and Novartis, and has served as an advisor to four U.S. presidential administrations.

Michael Abrams, Chief Financial Officer, has nearly 30 years of experience in finance, having served in executive roles, including CFO positions at Arch Therapeutics and FitLife Brands. His expertise spans investment banking, corporate finance, and business strategy.

Rick Panicucci, Chief Technology Officer, has more than 25 years of leadership in pharmaceutical manufacturing and process development. He has held key positions at Novartis, WuXi AppTec, and other major companies, leading multiple approved New Drug Applications.

Matthew Duffy, Chief Business Officer, NRx, Co-CEO of HOPE, has over 35 years of experience in biotechnology business development and investment banking. He has held leadership roles at Pfizer, MedImmune, and several financial institutions, specializing in corporate strategy and partnerships.

NRx Pharmaceuticals Inc. (NASDAQ: NRXP), closed Monday's trading session at $1.73, up 1.7647%, on 743,662 volume. The average volume for the last 3 months is 568,559 and the stock's 52-week low/high is $1.58/$3.84.

Recent News

• NRx Pharmaceuticals Inc. (NASDAQ: NRXP) - PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Appoints Prof. Joshua C. Brown As Chief Medical Innovation Officer
• BioMedNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Completes FDA Type C Meeting for NRX-100 NDA Pathway
• PsychedelicNewsBreaks - NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Licenses Real-World Evidence From 70,000 Patients to Support FDA Accelerated Approval of NRX-100

HeartBeam Inc. (NASDAQ: BEAT)

The QualityStocks Daily Newsletter would like to spotlight HeartBeam Inc. (NASDAQ: BEAT).

• The company’s core innovation, the HeartBeam System, is positioned as the first cable-free, high-fidelity ECG system capable of capturing the heart’s electrical signals from three distinct directions.
• HeartBeam’s strategy is built around addressing a long-standing gap in cardiac care.
• Looking forward, HeartBeam is focused on advancing both its hardware and software platforms.

HeartBeam (NASDAQ: BEAT) stands at a pivotal point in its development as a medical technology company focused on transforming how cardiac arrhythmias are detected, evaluated and monitored. Headquartered in Santa Clara, California, HeartBeam is building a platform designed starting with its FDA-cleared synthesized 12-lead ECG system to bring clinically meaningful ECG data out of traditional healthcare facilities and into more accessible, patient-centered settings.

HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care by providing advanced cardiac insights, announced that its management team will attend several investor and industry conferences in March 2026. CEO Robert Eno and CFO Timothy Cruickshank will participate in the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, including a webcast presentation on March 16, while also meeting with institutional and retail investors. The executives will also attend the 38th Annual ROTH Conference in Dana Point, California, on March 23-24, where Eno will join a panel on technologies advancing healthy aging. In addition, Eno, Founder and President Dr. Branislav Vajdic and Chief Commercial Officer Bryan Humbarger will attend ACC.26, the American College of Cardiology’s annual scientific conference on March 28-30, where the company will showcase its FDA-cleared HeartBeam System and demonstrate a working prototype of its 12-lead ECG extended wear patch to physicians and potential industry partners.

To view the full press release, visit https://ibn.fm/w6TnE

HeartBeam Inc. (NASDAQ: BEAT) is a medical technology company pioneering a new approach to cardiac care by delivering hospital-grade electrocardiogram (ECG) insights outside traditional clinical settings. Its proprietary platform supports a scalable app-based solution for real-time heart monitoring.

The company’s mission is to empower both patients and physicians with actionable cardiac data wherever symptoms begin, addressing a critical gap in the first hours of cardiac events. Through its connected cardiac care ecosystem, HeartBeam is establishing a new model for remote monitoring that deepens patient engagement and delivers more actionable insights for physicians. This approach is designed to obtain early diagnosis which could reduce time to treatment, improve outcomes, and lower costs across the healthcare continuum.

HeartBeam’s system aims to bring clinical-grade cardiac assessment into the home. HeartBeam is preparing for commercial launch as its 12-lead ECG synthesis software undergoes regulatory review, building on prior clearance of its 3D ECG system for arrhythmia assessment. The company plans to leverage its unique longitudinal ECG dataset and deep learning algorithms to advance predictive capabilities in the future.

HeartBeam is headquartered in Santa Clara, California.

Products

HeartBeam’s flagship innovation is its credit card-sized, cable-free ECG device that collects heart signals in three non-coplanar dimensions and synthesizes a 12-lead ECG. Cleared by the FDA in December 2024 for arrhythmia assessment, the HeartBeam System enables patients to capture high-fidelity heart data during symptomatic episodes, even outside a clinical environment.

The company’s pending 12-lead ECG synthesis software, developed from the same 3D signal acquisition, successfully met clinical endpoints in the VALID-ECG study and is currently under FDA review for arrhythmia assessment. This software combined with an on-demand cardiologist reader service is expected to form the backbone of HeartBeam’s commercial launch strategy, providing patients with access to a synthesized 12-lead ECG outside of the traditional hospital setting and enabling physician interpretation of patient ECGs from anywhere.

From the core, the team is building an ecosystem that includes integration with wearables, automated arrhythmia assessments, AI-driven wellness features, community features and trending insights. The ecosystem is intended to drive adoption and increase the overall value of the HeartBeam System.

Artificial Intelligence and Predictive Analytics

To enhance its diagnostic capabilities, HeartBeam is developing AI-powered arrhythmia detection algorithms to be validated in collaboration with Mount Sinai Heart. In early testing, these deep learning algorithms achieved diagnostic accuracy comparable to standard 12-lead ECGs when classifying atrial fibrillation, atrial flutter, and sinus rhythm.

Additionally, HeartBeam’s AI engine has the potential to transform routine monitoring into predictive power in the future. The company’s platform enables frequent readings, building a unique longitudinal ECG dataset unique that no one else offers. By leveraging deep learning on the repeated measurements, there is an opportunity to develop predictive capabilities, such as screening for hidden cardiac conditions and forecasting risk of future events. The unique longitudinal dataset will create a defensible data moat as the company continues to advance its AI program.

Market Opportunity

HeartBeam is targeting a large unmet need in cardiac care by delivering hospital-grade ECG diagnostics to patients outside of traditional healthcare settings. Cardiovascular disease is the leading cause of death worldwide, yet most cardiac events occur at home, where standard 12-lead ECGs are not available, leading to costly delays in diagnosis and treatment. HeartBeam’s FDA-cleared 3D ECG technology is designed to close this critical gap with on-demand, remote diagnostic capabilities.

The company’s initial commercialization strategy focuses on two distinct U.S. entry markets. The first includes approximately 500,000 elevated-risk patients in concierge care settings, representing a $250 million to $500 million annual revenue opportunity. The second addresses a larger direct-pay segment of 2.6 million elevated-risk individuals, with potential revenues of $1.3 billion to $2.6 billion annually. Future expansion may include reimbursement-driven pathways through Medicare Advantage, providers, and payer partnerships.

HeartBeam anticipates annual subscription pricing between $500 and $1,000 per patient, with roughly 50% gross margins on device costs and 70%+ on recurring revenue. Based on a model using five U.S. regions, each with an estimated 75,000 eligible patients, HeartBeam projects that just 10% adoption would generate approximately $20 million in gross profit—enough to reach cash flow break-even under current pricing and margin assumptions. Over time, the company’s longitudinal ECG dataset and predictive AI capabilities are expected to deliver additional value to healthcare systems, research institutions, and life science partners.

Leadership Team

Robert Eno, Chief Executive Officer and Director, brings over 30 years of experience in the medical technology industry, including leadership roles at HeartFlow, OptiMedica, and NeoGuide Systems. He joined HeartBeam as President in January 2023 and was appointed CEO in October 2024, later joining the board in May 2025 to support commercial growth.

Branislav Vajdic, Ph.D., Founder and Chief Technology Officer, is a semiconductor and medtech innovator who previously led product design teams at Intel and founded NewCardio. He holds over 20 patents and is the original architect of HeartBeam’s core technology.

Tim Cruickshank, Chief Financial Officer, oversees financial strategy and capital allocation. He works closely with the leadership team to support commercialization while maintaining financial discipline aligned with key regulatory milestones.

Peter Fitzgerald, M.D., Ph.D., Chief Medical Advisor, is Director of the Center for Cardiovascular Technology at Stanford and a seasoned clinical trialist with over 175 studies and 650 publications. He has founded over 20 medtech companies and advises the FDA on digital health analytics.

Ken Persen, Chief Technology Officer, has more than 28 years of experience in cardiac rhythm management and digital health. He previously served as CTO and CEO at LIVMOR and held engineering roles at Cameron Health and Guidant.

HeartBeam Inc. (NASDAQ: BEAT), closed Monday's trading session at $1.48, up 5.7143%, on 429,012 volume. The average volume for the last 3 months is 563,333 and the stock's 52-week low/high is $0.54/$4.

Recent News

• HeartBeam Inc. (NASDAQ: BEAT) - BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Schedules March 12 Conference Call to Review Q4 and Full-Year 2025 Results
• BioMedNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in ALIGN-ACS Pilot Study for Heart Attack Detection
• AINewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Announces Commercial Partnership With ClearCardio as First Customer and Strategic Investor

Soligenix Inc. (NASDAQ: SNGX)

The QualityStocks Daily Newsletter would like to spotlight Soligenix Inc. (NASDAQ: SNGX).

• “The EMA’s positive opinion signifies an important step for Soligenix as we continue to advance the program,” says company CEO.
• The designation provides incentives that may include protocol assistance, reduced regulatory fees and up to 10 years of market exclusivity following approval.
• Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body’s innate immune system rather than suppress it outright.

For patients living with rare inflammatory diseases, regulatory milestones can mark the difference between stalled research and meaningful therapeutic progress. A positive opinion from the European Medicines Agency (EMA) not only validates a drug’s scientific rationale but can also unlock development incentives that accelerate its path forward. In that context, Soligenix (NASDAQ: SNGX) , a late-stage biopharmaceutical company focused on developing treatments for rare diseases and areas of unmet medical need, announced that it has received a positive opinion from the EMA’s Committee for Orphan Medicinal Products for its pipeline product dusquetide in the treatment of Behcet’s disease.

Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases.

The company is actively advancing multiple late-stage clinical programs, including HyBryte™ (SGX301), a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL). Additional candidates in development target psoriasis (SGX302), oral mucositis (SGX942), and Behçet’s disease (SGX945), while its public health efforts focus on heat-stable vaccines for ricin poisoning (RiVax®), Ebola (SuVax™), and Marburg (MarVax™) viruses, that have been supported by non-dilutive government grants and contracts of approximately $60 million to date.

With a diversified pipeline, multiple orphan and fast-track designations, and collaborations with government agencies, Soligenix is uniquely positioned for potential regulatory approvals and commercialization.

The company is headquartered in Princeton, New Jersey.

Pipeline and Development Programs

Specialized BioTherapeutics

Soligenix’s Specialized BioTherapeutics division develops treatments for oncology and inflammatory diseases, focusing on conditions with few or no effective therapeutic options. HyBryte™ (synthetic hypericin) has completed a Phase 3 study for CTCL, demonstrating statistically significant efficacy, and a second confirmatory Phase 3 trial is actively enrolling patients to support potential regulatory submissions worldwide. If approved, it would be the first non-mutagenic photodynamic therapy for early-stage CTCL, addressing an unmet medical need. It has received orphan drug designations in the U.S. and Europe, as well as Fast Track designation in the U.S.

SGX302, a photodynamic therapy based on the same active ingredient as HyBryte™, is in clinical development for mild-to-moderate psoriasis, with positive Phase 1/2 proof-of-concept results, it is actively enrolling patients in a Phase 2a clinical trial.

SGX942, designed to reduce inflammation and tissue damage in oral mucositis associated with cancer treatment, is progressing as a potential first-in-class therapy.
SGX945, targeting aphthous ulcers in Behçet’s disease, is actively enrolling in a Phase 2a clinical trial and has received fast-track designation, highlighting the urgency of developing effective treatments for this rare inflammatory condition.

Public Health Solutions

The company’s Public Health Solutions segment focuses on medical countermeasures for biothreats and emerging infectious diseases, leveraging non-dilutive government funding to advance its programs. RiVax®, a ricin toxin vaccine, has demonstrated strong preclinical and early clinical results and may be eligible for government procurement under the Strategic National Stockpile initiative.

The company’s RiVax®, as well as its vaccine candidates for Ebola and Marburg viruses are based on its proprietary ThermoVax® technology, which stabilizes vaccines for long-term storage without refrigeration. This approach could be transformative in regions where maintaining cold-chain logistics is challenging.

The ongoing development of these vaccines is supported by funding from NIH, BARDA, and DTRA, with the potential for up to three priority review vouchers (PRVs) upon regulatory approval, to be used for future programs or sold. Notably, PRVs have previously sold for roughly $100 million.

Market Opportunity

Soligenix targets markets with significant commercial potential, focusing on rare diseases and biodefense applications. HyBryte™ addresses CTCL, a disease affecting over 68,000 patients across the U.S. and Europe, with a total market opportunity exceeding $250 million. SGX302, the company’s therapy for mild-to-moderate psoriasis, serves a much larger population, as over eight million people in the U.S. are affected by the condition, representing a global market opportunity exceeding $1 billion.

SGX942, developed for oral mucositis in head and neck cancer patients, is aimed at a market worth more than $500 million, while SGX945 for Behçet’s disease serves a niche segment valued at over $200 million worldwide.

In addition to its rare disease programs, Soligenix’s Public Health Solutions division has the potential to generate significant revenue through government procurement contracts. By focusing on both orphan drug markets and government-funded biodefense initiatives, Soligenix has positioned itself for sustained revenue growth through multiple high-value opportunities.

Leadership Team

Christopher J. Schaber, PhD, Chairman, President & CEO, brings to the company more than 35 years of experience in the biopharmaceutical industry. Before joining Soligenix, he held senior and operational leadership roles at Discovery Laboratories, Acute Therapeutics, Ohmeda Pharmaceuticals, The Liposome Company, and Wyeth Ayerst Laboratories. He has extensive expertise in drug development, regulatory affairs, and corporate strategy, positioning him to drive Soligenix’s growth and advancement toward commercialization.

Richard Straube, MD, Chief Medical Officer, has more than 35 years of experience in drug development and clinical research. Prior to joining Soligenix, he held key leadership roles at Stealth Peptides, INO Therapeutics, Ohmeda Pharmaceuticals, and Centocor. Throughout his career, he has played a crucial role in bringing innovative therapies to market, particularly in inflammatory diseases and immunology, making him a valuable asset in advancing Soligenix’s late-stage clinical programs.

Oreola Donini, PhD, Chief Scientific Officer, has more than 20 years of experience in pharmaceutical research and development, with expertise in immunology, inflammation, and rare diseases. Before joining Soligenix, she held leadership positions at Inimex Pharmaceuticals, ESSA Pharma, and Kinetek Pharmaceuticals, where she worked on novel drug discovery and translational medicine. Her experience in preclinical research and product development supports Soligenix’s continued innovation in biopharmaceuticals.

Jonathan Guarino, CPA, CGMA, Chief Financial Officer, has over 25 years of experience in corporate finance and strategic financial planning. Before joining Soligenix, he held financial leadership positions at Hepion Pharmaceuticals, Covance, BlackRock, and Barnes & Noble. His expertise in financial management, accounting, and capital markets plays a critical role in Soligenix’s financial strategy and operational efficiency.

Soligenix Inc. (NASDAQ: SNGX), closed Monday's trading session at $1.2, up 0.8403361%, on 92,174 volume. The average volume for the last 3 months is 140,183 and the stock's 52-week low/high is $1.02/$6.2299.

Recent News

• Soligenix Inc. (NASDAQ: SNGX) - Soligenix Inc. (NASDAQ: SNGX) Leverages Platform Science for Broader Therapeutic Reach
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) Receives Positive EMA Orphan Drug Opinion for Dusquetide in Behçet Disease
• BioMedNewsBreaks - Soligenix Inc. (NASDAQ: SNGX) CEO to Present at BIO Investment & Growth Summit

Renewal Fuels Inc. (OTC: RNWF)

The QualityStocks Daily Newsletter would like to spotlight Renewal Fuels Inc. (OTC: RNWF).

• Appointment of fusion researcher Fabrice David adds scientific oversight as commercialization plans advance.
• Travis Yakimishyn joins as Chief Electrical & Power Systems Officer to lead utility-scale integration.
• The company is transitioning to American Fusion Inc. following its merger with Kepler Fusion Technologies, with filing and audits nearing completion as the company prepares for SEC reporting status.
• Management reiterates goal of deploying a 100-megawatt operational unit by year-end 2026, with Kepler‘s plan to sell electricity on a per-kilowatt basis to utilities and industrial customers.

Renewal Fuels (OTC: RNWF) (d/b/a American Fusion), an advanced energy platform company focused on the development and commercialization of fusion energy technologies, is working to advance its Texatron(TM) aneutronic fusion system, while simultaneously strengthening governance, engineering leadership and regulatory positioning.

Renewal Fuels Inc. (OTC: RNWF) (d/b/a American Fusion) is an advanced energy platform company focused on building a scalable, infrastructure-grade fusion energy business through its wholly owned subsidiary, Kepler Fusion Technologies. Following a completed reverse merger with Kepler, the company has repositioned itself around the development and long-term commercialization of deployable fusion power systems designed for real-world industrial and infrastructure use rather than experimental research programs.

The company’s strategy centers on pairing proprietary fusion technology with disciplined governance, intellectual property development, and a public-company operating framework intended to support long-duration value creation. Management has emphasized transparency, regulatory readiness, and institutional credibility as foundational elements alongside continued technical progress.

Renewal Fuels is in the process of transitioning its public identity to American Fusion to reflect its strategic focus on advanced fusion energy infrastructure and commercialization.

The company is based in Southlake, Texas.

Kepler Texatron™

Through wholly owned subsidiary, Kepler Fusion Technologies, the company is developing the Texatron™ aneutronic fusion platform, a compact, pulsed fusion system engineered specifically for commercial and infrastructure-grade deployment. Unlike steady-state fusion concepts that prioritize laboratory demonstration, the Texatron™ operates in controlled cycles designed to support modular scalability, redundancy, and distributed installation across multiple end markets.

The platform is optimized around a Deuterium–Helium-3 fuel pathway that enables direct electrical energy conversion, reducing reliance on traditional steam cycles and minimizing neutron-related material degradation. This design supports a smaller physical footprint and greater flexibility for deployment in grid-constrained or mission-critical environments such as data centers, industrial facilities, defense installations, and remote locations.

Kepler’s commercialization model is structured around a Power-as-a-Service approach under which the company intends to retain ownership of its fusion units and sell electricity to customers under long-term contractual arrangements. This infrastructure-oriented model is designed to align system deployment with predictable, recurring revenue while allowing for fleet-based scaling over time. The platform is supported by a broad and expanding intellectual property estate encompassing reactor architecture, energy conversion systems, control technologies, manufacturing processes, and deployment methodologies.

Market Opportunity

U.S. electricity demand has re-entered a period of sustained growth following nearly two decades of relative stagnation, according to data from the U.S. Energy Information Administration. After years in which efficiency gains and structural economic shifts largely offset population and economic growth, electricity consumption has increased meaningfully since 2020 and is forecast to continue rising through at least the middle of the decade.

Recent and projected growth is being driven primarily by the commercial and industrial sectors, with data centers, advanced manufacturing, and other power-intensive operations accounting for a disproportionate share of incremental demand. These segments tend to require continuous, non-intermittent electricity supply, placing increased pressure on existing generation and transmission infrastructure.

This shift underscores a growing need for reliable baseload power sources that can be deployed without extensive new transmission build-out and that align with emissions-reduction objectives. Fusion-based energy systems designed for distributed, infrastructure-grade deployment represent a potential long-term solution for meeting rising demand in environments where reliability, resilience, and scalability are critical.

Leadership Team

Richard Hawkins, Chairman and Chief Executive Officer, has overseen the company’s strategic reset, corporate restructuring, and transition toward an advanced fusion energy platform, with responsibility for governance, capital markets strategy, and long-term corporate development.

Brent Nelson, Chief Executive Officer of Kepler Fusion Technologies, brings extensive experience in energy systems and commercialization strategy and leads the development, validation, and deployment roadmap for the Texatron™ fusion platform, as well as Kepler’s intellectual property and operating model.

Renewal Fuels Inc. (OTC: RNWF), closed Monday's trading session at $0.0377, up 13.5542%, on 13,720,648 volume. The average volume for the last 3 months is 16,070,330 and the stock's 52-week low/high is $0.000001/$0.045.

Recent News

• Renewal Fuels Inc. (OTC: RNWF) - GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Issues Commentary on Energy Security Amid Middle East Escalation, Highlights Texatron(TM) Fusion Progress
• GreenEnergyBreaks - Renewal Fuels, Inc. (OTC: RNWF) Closes Kepler Fusion Transaction, Advances SEC Reporting and American Fusion Transition
• Renewal Fuels Inc. (RNWF) Strengthens Leadership Bench and IP Strategy as It Drives New Approach Toward Commercial Fusion Energy

Frontieras North America Inc.

The QualityStocks Daily Newsletter would like to spotlight Frontieras North America Inc.

• Frontieras’ patent portfolio includes protection across five continents and nine countries, covering approximately 85% of global coal production.
• The FASForm(TM) process is designed as a closed-loop, zero-waste system that converts coal into multiple market-ready energy and industrial products.
• Long-term feedstock and product offtake frameworks are in place for the company’s flagship commercial facility.
• The Mason County project is structured as a large-scale infrastructure development with established engineering, construction, operations, logistics, and insurance partners.
• Frontieras’ commercialization strategy focuses on replicable facilities serving established energy and chemicals markets with existing demand.

Frontieras North America is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

Frontieras North America Inc. is an energy and environmental technology company focused on redefining how coal and other solid hydrocarbons are utilized within modern energy and industrial systems. Rather than treating coal as a fuel to be burned, the company applies patented processing technology to reform solid hydrocarbons into multiple market-ready energy and industrial products designed for existing global markets.

The company’s approach is rooted in extracting greater value from abundant natural resources through industrial innovation, addressing inefficiencies historically associated with conventional coal use. By separating coal into gases, liquids, and purified solid carbon, Frontieras positions coal as a versatile feedstock capable of supporting transportation, manufacturing, agriculture, and industrial infrastructure demand.

Frontieras emphasizes closed-loop, zero-waste processing as a means of producing energy products more efficiently while reducing emissions and unused byproducts.

Products and Projects

Frontieras’ core platform is FASForm™, a patented Solid Carbon Fractionation process that deconstructs coal by extracting volatiles, moisture, and contaminants. The process produces hydrogen, methane, naphtha, diesel, aviation fuel, and FASCarbon™, a low-sulfur technical carbon product.

The company is developing its first commercial-scale FASForm™ facility in Mason County, West Virginia, an estimated $850 million project designed to process approximately 7,500 tons of coal per day, or about 2.7 million tons annually. The facility is supported by a 10-year feedstock MOU using Pittsburgh #8 coal and a 10-year offtake LOI covering 100% of produced fuels, FASCarbon™, sulfuric acid, and fertilizer.

Engineering, construction, operations, logistics, and insurance partners are under executed agreements, and the project has completed FEL 1 and FEL 2, with substantial FEL 3 underway. Following its initial Mason County development, Frontieras plans to deploy additional FASForm™ facilities in West Virginia, Texas, and Wyoming, with longer-term international deployment in markets where its patent portfolio is in force.

Market Opportunity

Frontieras targets established global energy and chemicals markets with a combined estimated value exceeding $2.1 trillion. The company’s product portfolio aligns with large, existing demand across diesel, hydrogen, naphtha, jet fuel, technical carbon – coke, industrial chemicals, and fertilizer markets. These products are core industrial inputs with long-established supply chains, entrenched end-use applications, and global pricing benchmarks, reducing reliance on the creation of new or speculative markets.

These markets serve essential roles across transportation, agriculture, industrial machinery, aviation, steel manufacturing, petrochemicals, and food production, supporting continuous demand driven by infrastructure, manufacturing, and population growth. The planned design capacity of the first FASForm™ facility is approximately 7,500 tons per day, or about 2.7 million tons annually — equivalent to roughly 0.5% of current U.S. coal production. This design framework is intended to enable Frontieras to scale output incrementally while remaining aligned with existing market capacity, logistics networks, and demand profiles.

Leadership Team

Matthew McKean, Co-Founder & Chief Executive Officer, leads Frontieras’ overall strategy and execution and brings more than 25 years of experience across finance, operations, and business leadership. He previously co-founded a mortgage banking firm that grew into one of the largest originators in the southwestern U.S. before a successful exit, followed by senior leadership roles within large real estate finance organizations. McKean has been an active member of the CEO mentoring organization Vistage, advising companies across construction, finance, infrastructure, and consumer sectors. He holds a Bachelor of Science in Human Nutrition with an emphasis in Chemistry from Arizona State University and completed pre-med coursework.

Josephe Witherspoon, P.E., Co-Founder & Chief Technology Officer, is the inventor of the FASForm™ process and the author of the company’s core patents. He brings extensive experience in petroleum refining, natural gas processing, and chemical engineering from senior roles at Chevron, Enterprise Products, Sinclair Oil, and Marathon Petroleum. As a Process Design Engineer and Major Capital Project Manager, Witherspoon has led projects delivering significant operational and economic improvements. He holds a Bachelor of Science in Chemical and Fuels Engineering from the University of Utah and is a licensed Professional Engineer.

Andrea Moran, Chief Commercial Officer, oversees Frontieras’ commercialization strategy, capital formation, and go-to-market execution. She brings more than 25 years of experience in operations, management, and business development across the energy and infrastructure sectors. Prior to Frontieras, Moran served as Co-Founder and Vice President of Business Development at Yield Power Group, a project finance firm supporting energy and infrastructure projects ranging from $100 million to over $1 billion. She holds a Bachelor of Science in Political Science from the University of Wisconsin and serves on philanthropic and advisory boards.

José López, Chief Financial Officer, leads Frontieras’ financial strategy, operations, and capital planning. He brings over 20 years of experience in global finance and accounting, including senior roles at multinational public companies. López began his career at PwC’s external assurance practice, working across Houston, London, and The Hague. His background includes SEC reporting, corporate governance, FP&A, mergers and acquisitions, and capital markets transactions. He holds a Bachelor of Science in Accounting and Finance from the University of Houston–Clear Lake and is a licensed Certified Public Accountant.

Recent News

• Frontieras North America Inc. - InvestorNewsBreaks – Frontieras North America Advances Clean Coal Revival With $850M West Virginia FASForm(TM) Facility
• How Frontieras North America Is Expanding Access to Early-Stage Energy Investment
• Frontieras North America Launches FASGEN™: A Breakthrough Platform to Preserve, Expand, and Revalue the U.S. Coal Fleet as AI Energy Demand Explodes

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM)

The QualityStocks Daily Newsletter would like to spotlight Silvercorp Metals Inc. (TSX.V: SVM) (NYSE American: SVM).

This article has been disseminated on behalf of Silvercorp Metals and may include paid advertising.

Silvercorp Metals (TSX: SVM) (NYSE American: SVM) announced the filing of an updated Mineral Resource Estimate for the Tulkubash and Kyzyltash Chaarat Gold Projects in the Republic of Kyrgyzstan through a National Instrument 43-101 technical report titled “NI 43-101 Technical Report and Updated Mineral Resource Estimate for the Tulkubash And Kyzyltash Chaarat Gold Project Republic Of Kyrgyzstan,” effective Oct. 15, 2025. The report was prepared in accordance with Canadian Securities Administrators’ National Instrument 43-101 – Standards of Disclosure for Mineral Projects and is available on the company’s website as well as under its profile on SEDAR+ and EDGAR.

To view the full press release, visit https://ibn.fm/Y1B8s

Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) is a Canadian mining company producing silver, gold, lead, and zinc, with a long history of profitability and growth. The company focuses on creating shareholder value by generating free cash flow from long-life mines, expanding through organic growth opportunities in China and Ecuador, and pursuing strategic mergers and acquisitions. Silvercorp has built a reputation as a low-cost producer with a commitment to responsible mining practices.

With over 18 years of operating experience, Silvercorp has developed a diversified portfolio of mining assets and investments in China, Ecuador, and Bolivia. The company leverages its expertise in exploration and operational efficiency to enhance the value of its projects while maintaining a strong balance sheet. Silvercorp’s disciplined approach to mine expansion and resource development ensures long-term sustainable growth.

The company’s mission is to build and operate profitable mines that generate sustainable economic, social, and environmental benefits for stakeholders. Silvercorp is committed to responsible mining, with a focus on environmental stewardship and community engagement.

The company is headquartered in Vancouver, Canada.

Portfolio

Silvercorp operates a diverse portfolio of producing mines, construction-stage projects, and exploration assets across multiple jurisdictions. The company focuses on optimizing production from existing operations while strategically advancing new projects to drive future growth.

• Ying Mining District (China) – The company’s flagship operation consists of several underground mines producing silver, gold, lead and zinc in concentrates. In fiscal 2025, Ying produced 6.9 million ounces of silver and 7,495 ounces of gold, along with lead and zinc by-products. Fiscal 2026 guidance calls for continued production growth as ongoing mine optimization efforts continue to bear fruit.
• GC Mine (China) – A silver-lead-zinc mine with a history of consistent production and ongoing resource expansion through drilling. While production dipped slightly in fiscal 2025, output is expected to increase in fiscal 2026.
• El Domo (Ecuador) – A fully-permitted, copper-gold project under construction. In April 2025, Silvercorp announced a detailed and fully-funded $240.5 million construction plan. Major contracts have been awarded and construction activities are underway, with commissioning expected by December 2026.
• Condor Project (Ecuador) – A gold exploration asset with significant resources. In May 2025, Silvercorp published an updated mineral resource estimate focusing on high-grade underground zones. A revised PEA is expected by the end of 2025, alongside continued permitting and community engagement efforts.
• Kuanping Project (China) – A permitted gold-lead-zinc satellite project north of Ying. Mine construction is underway and Kuanping will be an underground mine with ore to be milled at the Ying complex.
• BYP Mine (China) – A gold-lead-zinc project that operated previously and is now undergoing permitting as a gold mine.
• Bolivian Assets – Silvercorp holds a 28% stake in New Pacific Metals (TSX: NUAG, NYSE American: NEWP), providing indirect exposure to two world class silver projects: Silver Sand and Carangas.

Through its diversified portfolio, Silvercorp delivers exposure to operations generating growing cash-flow, as well as high-potential growth projects that will create long-term value for shareholders.

Market Opportunity

The global demand for silver, gold, and base metals remains strong, driven by industrial applications, investment demand, and renewable energy initiatives. Silvercorp is well positioned to capitalize on rising silver demand, particularly in China, where 80% of the world’s solar panels are manufactured—an industry heavily reliant on silver.

Ecuador’s mining sector is experiencing rapid growth, with government support for foreign investment and infrastructure improvements. Mining exports in the country surged from $275 million in 2018 to $3.3 billion in 2023, highlighting the sector’s increasing economic importance. Silvercorp’s El Domo and Condor projects are poised to become key contributors to Ecuador’s mining expansion.

Industry forecasts indicate continued growth in silver and base metal prices, benefiting producers with strong operational performance and cost controls. Silvercorp’s diversified asset base and low-cost production profile provide resilience against market fluctuations, positioning the company for long-term value creation.

Leadership Team

Rui Feng, Ph.D., Chairman & CEO, founded Silvercorp and has over 30 years of experience in mineral exploration and mining. He has been instrumental in leading the company’s strategic vision, transforming it into a profitable, low-cost silver producer with a diversified asset base. Under his leadership, Silvercorp has expanded its global footprint, acquiring and developing high-value mining projects across China, Ecuador, and Bolivia. Dr. Feng’s expertise in geology and resource development has contributed to major mineral discoveries, and his disciplined approach to capital allocation has positioned the company for long-term growth.

Derek Liu, MBA, CGA, CPA, Chief Financial Officer, brings over two decades of financial leadership experience in the mining sector, overseeing capital allocation, financial strategy, and risk management. He has played a crucial role in maintaining Silvercorp’s strong balance sheet and financial discipline, ensuring the company remains well-capitalized for organic growth and strategic acquisitions. His expertise in financial planning, compliance, and investor relations has supported Silvercorp’s continued profitability and operational efficiency in a competitive global mining landscape.

Lon Shaver, CFA, President, has extensive experience in corporate finance, equity research, and capital markets, providing strategic guidance on business development and investor relations. Before joining Silvercorp, he held senior roles in investment banking and asset management, where he advised mining companies on financing, mergers, and acquisitions. His deep understanding of capital markets and industry dynamics helps drive Silvercorp’s corporate growth initiatives, enhance shareholder value, and strengthen relationships with institutional investors and stakeholders.

Silvercorp Metals Inc. (NYSE American: SVM), closed Monday's trading session at $11.57, off by 2.1978%, on 6,663,095 volume. The average volume for the last 3 months is 6,209,131 and the stock's 52-week low/high is $3.15/$14.

Recent News

• Silvercorp Metals Inc. (NYSE American: SVM) (TSX: SVM) - BillionDollarBreaks - Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Reports Record Revenue and Cash Flow in Q3 Fiscal 2026
• RockBreaks - Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Updates El Domo Project Construction Budget to $284 Million
• BillionDollarBreaks - Silvercorp Metals Inc. (TSX: SVM) (NYSE American: SVM) Files Preliminary Economic Assessment for Condor Gold Project

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF)

The QualityStocks Daily Newsletter would like to spotlight SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF).

This article has been disseminated on behalf of SPARC AI Inc. and may include paid advertising.

SPARC AI (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) announced that it has established the operational environment for its Overwatch GPS-denied navigation and targeting platform for the Ukraine market and expects to deliver the system this week as part of operational field testing first announced in February 2026. The testing will evaluate the platform’s navigation and target acquisition capabilities under persistent GPS jamming and degraded signal conditions, providing a key validation milestone for defense and security applications in contested environments. In conjunction with the deployment, the company also enhanced its data flywheel architecture, enabling real-world operational data from deployments — including Ukraine-developed drone platforms — to feed directly into Overwatch’s sensor fusion machine learning models, allowing targeting and geo-location accuracy to continuously improve as additional data is collected

To view the full press release, visit https://ibn.fm/dsM2s

SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) develops next-generation, GPS-free target acquisition system and autonomous navigation software for drones and edge devices. Its zero-signature technology delivers real-time detection, tracking, and behavioral insights without reliance on radar, lidar, or heavy sensors. The company’s platform transforms unmanned systems into autonomous tools capable of identifying and engaging targets in GPS-denied environments.

The company’s vision is to redefine situational awareness by merging advanced mathematics, AI modeling, and edge computing into a unified intelligence architecture. SPARC AI aims to empower defense, rescue, and commercial organizations to operate safely and effectively in signal-contested environments where traditional navigation systems fail.

Its mission is to build the world’s most trusted geolocation intelligence platform that operates without GPS, enabling seamless interoperability across air, land, and sea devices.

SPARC AI is headquartered in Toronto, Canada.

Technology

SPARC AI’s technology suite delivers precision target acquisition, navigation, and autonomous intelligence in environments where GPS and traditional sensors fail. At its core is the Target Acquisition System, a software-only solution that determines the geolocation of any visible object using camera telemetry data. By removing the need for specialized hardware like lasers, radar, or lidar, the platform reduces weight, power use, and cost. Built on advanced mathematical modeling, it constructs a 3D understanding of terrain and position, achieving GPS-level accuracy in a zero-signature configuration suited for defense, rescue, and commercial operations.

SPARC AI Mobile extends this capability to handheld and field-issued devices, allowing operators to mark and transmit target coordinates directly from smartphones or rugged tablets. Once a target is identified, the device relays the coordinates to a connected drone, which autonomously navigates to the location for reconnaissance or engagement. The mobile system maintains accuracy even in GPS-jammed or degraded environments, turning each device into a connected node within a broader distributed network.

The company’s GPS-Denied Navigation engine enables mission planning and execution without satellite signals. Operators can design flight paths, define perimeters, and simulate routes to identify optimal vantage points and minimize resource use. Counter-surveillance and threat-prediction tools model adversarial visibility, helping users avoid detection and maximize ground coverage. Together, these capabilities form the foundation of SPARC AI’s software architecture, providing the intelligence backbone for its integrated command platform.

Overwatch Target Intelligence

Overwatch unifies all SPARC AI technologies, including its Target Acquisition, Mobile, and Navigation systems, into a single mission-ready platform that fuses detection, classification, tracking, and navigation in real time. It transforms drones and robotic systems into fully autonomous intelligence assets by synchronizing data across connected devices. The platform’s zero-signature design ensures complete operational security, allowing defense and rescue teams to conduct surveillance, reconnaissance, and engagement without GPS or active sensors.

Within Overwatch, the ATLAS Visibility Intelligence Engine enhances mission planning and reconnaissance through 2D and 3D visualization. Users can simulate line-of-sight coverage from any altitude, identify unseen or occluded areas, and optimize routes for surveillance or search and rescue. Operating entirely through software, ATLAS produces high-fidelity visibility data without mapping drones or additional power consumption, providing a lightweight, silent, and sensor-free alternative to lidar-based systems.

The SPARC AI SDK and open API framework extend Overwatch’s interoperability. Developers can embed SPARC AI’s intelligence into third-party systems such as PX4- and ArduPilot-powered drones, the world’s most widely used open-source flight platforms. The SDK provides REST APIs with bindings for Python, C++, and JavaScript and supports hardware including NVIDIA Jetson, Qualcomm Robotics RB5, and Raspberry Pi. Through these integrations, Overwatch serves as the command and intelligence layer of SPARC AI’s ecosystem, linking distributed drones, sensors, and edge devices into a coordinated autonomous network that operates entirely without GPS.

Market Opportunity

SPARC AI operates within the rapidly expanding defense, security, and commercial drone markets projected to exceed $100 billion over the next decade. The company’s software-defined approach addresses the global demand for autonomous systems capable of performing in denied, degraded, intermittent, and limited (DDIL) environments, positioning SPARC AI at the forefront of next-generation geolocation and targeting solutions.

Fortune Business Insights projects the global commercial drone market will reach approximately $65.25 billion by 2032, while Grand View Research estimates the combined drone hardware and services market will grow to $163.6 billion by 2030. With its per-device subscription model and integration across drones and robotic systems, SPARC AI is structured to capture recurring revenue from this accelerating adoption of GPS-denied intelligence technologies.

Leadership Team

Anoosh Manzoori, CEO, brings extensive experience as a technology entrepreneur, investor, and director, having founded, scaled, and exited multiple high-tech companies. He has taken five companies public, served on seven public company boards, and invested in innovations spanning cloud, fintech, biotech, IoT, defense, and AI.

Justin Hanka, Director, is an investment banking professional with 25 years of experience in mergers and acquisitions and capital markets. He has held executive roles at high-growth companies including iSelect.com.au and Helpmechoose, achieving multiple successful exits.

Anthony Haberfield, Director, is an international financial services executive with 30 years of experience across the Asia Pacific region, specializing in strategy, transformation, procurement, and emerging technology.

SPARC AI Inc. (OTCQB: SPAIF), closed Monday's trading session at $1.01, off by 6.308%, on 75,585 volume. The average volume for the last 3 months is 123,380 and the stock's 52-week low/high is $0.0792/$1.36.

Recent News

• SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) - Sparc AI Inc. (CSE: SPAI) (OTC: SPAIF) Positioned to Benefit from Canada's Defense Industrial Strategy and the Global Shift Toward Sovereign AI Capabilities
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Appoints Matt McCrann As CEO Of U.S. Subsidiary
• TechMediaBreaks - SPARC AI Inc. (CSE: SPAI) (OTCQB: SPAIF) (Frankfurt: 5OV0) Expands Into Ukraine With GPS-Denied Navigation Partnership

Wearable Devices Ltd. (NASDAQ: WLDS)

The QualityStocks Daily Newsletter would like to spotlight Wearable Devices Ltd. (NASDAQ: WLDS).

Wearable Devices (NASDAQ: WLDS) , a technology growth company specializing in artificial intelligence-powered touchless sensing wearables, announced it will implement a one-for-three reverse split of its ordinary shares and tradable warrants, effective when trading begins on a split-adjusted basis on March 11, 2026. The action is intended to increase the company’s per-share trading price to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. Following the reverse split, the number of issued and outstanding ordinary shares will be reduced from 10,593,227 to approximately 3,531,076, while publicly held warrants will decrease from 98,589 to about 32,863, with trading to continue under the existing ticker symbols “WLDS” and “WLDSW.” The move was approved by shareholders at a Feb. 19, 2026 special meeting, and the company expects the reverse split to maintain proportional ownership among shareholders, subject to rounding adjustments for fractional shares.

To view the full press release, visit https://ibn.fm/wLOiS

Wearable Devices Ltd. (NASDAQ: WLDS) is a growth-stage technology company pioneering the next generation of human-computer interaction through AI-powered neural input wearables. Mudra, its proprietary wrist-worn technology, enables touchless, gesture-based control of digital devices, offering users a seamless, intuitive interface through subtle finger and hand movements. Since introducing its technology to the market in 2014, the company has pursued both business-to-business (B2B) and business-to-consumer (B2C) strategies through a dual-channel model.

The company believes the future of technology should begin with the human. Wearable Devices envisions decoding the human body to enable context-aware AI-powered technology that listens, learns, and adapts – to us.

The company envisions a future where human intent becomes the language of technology. Through non-invasive neural sensing and adaptive algorithms, the company enables more natural, personalized, and intuitive interactions with computers.

The company is headquartered in Yokneam Illit, Israel.

Products

Neural control has entered the market: commercially available since 2023 with the Mudra Band and already used by thousands of users worldwide. With its product line, including Mudra Band and Mudra Link, the company has introduced the world’s first wrist-worn neural interfaces, enabling intuitive, touchless control through natural micro-gestures: subtle finger movements and wrist flicks. Whether streaming media, controlling smart devices, or interacting with AR glasses, Mudra brings neural input into everyday life.

This early adoption isn’t just validation — it’s acceleration. With real users engaging in real environments, the company is learning fast, improving faster, and shaping a product that grows more refined with every interaction.

Mudra Band

Mudra Band is the company’s flagship B2C product, designed as a sleek, aftermarket accessory for the Apple Watch. It uses patented sEMG sensors to detect neural signals from the wrist and translates them into real-time digital commands. This allows users to control and streamline interactions between the iPhone, iPad, MacBook, and Apple TV using familiar micro-gestures like taps, pinches, or swipes — all without touching a screen.

The device features a high-resolution analog front end, IMU integration, adaptive machine learning, and ergonomic form factors for all-day comfort. Users can toggle between multiple Apple devices using the Mudra Band’s dedicated Apple Watch face, enabling a fully connected, touchless experience. The Mudra Band is optimized for low-latency, high-accuracy interactions and supports a wide range of digital applications. The Mudra Band received a CES 2021 Innovation Award.

Mudra Link

Mudra Link expands the company’s reach beyond the Apple ecosystem, offering compatibility with Android, Windows, and AR/XR platforms. The product includes the innovative Gesture Mapper feature, allowing users to assign personalized commands to gestures such as tap, pinch, flick, or twist. This functionality replaces or augments traditional input methods, supporting media controls, pointer input, and full directional mapping. A key feature of Mudra Link is its dual-mode input system (mouse mode or D-pad mode), empowering users to personalize control schemes across devices, operating systems, and user interfaces.

Mudra Link is recognized for its ergonomic design, lightweight build, and plug-and-play ease of use. It supports native integration with AR glasses from leading manufacturers and received a CES 2025 Innovation Award.

Mudra DevKit and Integration

In parallel with its consumer devices, Wearable Devices offers a Mudra Developer Kit (MDK) and integration program for enterprise and OEM partners. The MDK includes full-stack tools (hardware bands, SDK, APIs, and sample code) that allow developers and original equipment manufacturers to embed Mudra’s neural sensing capabilities into their own products and applications. For example, an AR headset maker can integrate Mudra’s sensors to enable native hand-gesture input, or a software developer can use Mudra’s API to track user gestures for novel interactions.

The MDK supports both Android and iOS and even provides real-time neural raw signal monitoring for research and prototyping. This B2B offering not only expands Mudra technology into new environments such as industrial automation, robotics, and gaming peripherals, but also fosters a broader ecosystem of Mudra-powered solutions. By lowering the barrier for others to adopt its AI gesture recognition engine, Wearable Devices accelerates innovation and garners strategic relationships.

The MDK and related licensing offerings illustrate Wearable Devices’ push-pull strategy: selling consumer products today, while seeding ‘Mudra inside’ into other companies’ devices tomorrow.

Market Opportunity & Strategy

Wearable Devices operates at the intersection of neural interfaces, wearable computing, and the rapidly expanding AR/XR sector. According to MarketsandMarkets, the global AR and VR market is projected to grow from $22.12 billion in 2024 to $96.32 billion by 2029, at a CAGR of 34.2%. The rising demand for natural, hands-free input methods positions neural wearables like Mudra as foundational components in spatial computing and smart environments.

Additionally, the health monitoring wearables market is gaining traction as neural biosignals become a promising data source. The company’s LMM (Large Motor Unit Action Potential Model) platform is being explored for predictive health monitoring, cognitive state tracking, and performance analytics. Government-level support, such as advocacy from the U.S. Secretary of Health and Human Services, further validates the sector’s momentum.

Combined with patent-protected technology and strategic alliances with companies like Qualcomm, TCL-RayNeo™, and Media Exceed, Wearable Devices is well-positioned to capture value across consumer, enterprise, and healthcare verticals.

The company’s phased market strategy anticipates this:

• Phase 1 – Enthusiast Consumer Adoption: Introduce Mudra Band as an add-on for Apple Watch (tapping into a passionate user base of early adopters and tech enthusiasts). Achieve proof-of-concept and get market feedback. This phase built brand credibility and seeded a community of users.
• Phase 2 – Expand Platform & Ecosystem: Launch Mudra Link for all users and open the Mudra SDK to developers and B2B partners. Focus on the XR/AR market and tech-savvy consumers, while enabling enterprise use-cases through the Developer Kit and strategic partnerships. The company is actively showcasing its tech to industry leaders and integrating with their platforms.
• Phase 3 – Leverage Data & Enter New Verticals: With a growing user base, Wearable Devices is collecting an invaluable dataset of neural signals and usage patterns. If data is the new oil for AI, neural signals will power the next computing revolution — enabling machines to understand human intent in real time. This fuels its Large Motor-Unit Action Potential Model (LMM) – a bio-signal intelligence platform that continuously learns from neural data to improve accuracy and enable new applications. One major new vertical is digital health and wellness: Wearable Devices is adapting its tech to track physiological and cognitive indicators from the wrist. Because the Mudra sensors capture muscle activation signals, they can potentially detect patterns related to stress, fatigue, focus, and even early signs of health conditions before traditional symptoms appear, and Wearable Devices recently announced it is expanding LMM into predictive health monitoring and cognitive analytics. This means the company could offer solutions for workplace productivity (measuring alertness), athletic training (muscle fatigue analytics), or preventive healthcare (flagging neuromuscular irregularities) – vastly broadening its addressable market. Through monitor applications, the vision is to go from controlling devices to also understanding the user, providing actionable bio-insights. The LMM platform’s AI continuously adapts to each individual’s neural profile, enabling truly personalized and proactive applications.
• Phase 4 – Ubiquitous Adoption via B2B Integration: Finally, Wearable Devices plans to drive mass adoption by aligning with major consumer tech players. By making its Mudra Data Platform available to enterprises, OEMs, and app developers, the company positions itself as the backbone for neural interaction services. By “laying the groundwork for the next neural frontier”, Wearable Devices is ensuring that when the tech giants move to adopt neural input, its platform is the mature, data-rich standard ready to be deployed.

Through these phased efforts, Wearable Devices balances B2C and B2B paths. It generates near-term revenues and user feedback via direct consumer product sales, while simultaneously developing long-term enterprise relationships and intellectual property value. This dual model not only diversifies revenue streams but also reinforces the technology’s credibility: consumer adoption demonstrates demand and usability, which in turn attracts enterprise interest, creating a virtuous cycle.

Leadership Team

Asher Dahan, Chief Executive Officer, co-founded Wearable Devices Ltd. in 2014 and has served as CEO and director since 2016. He is a seasoned executive with proven expertise in strategic planning, project execution, and business leadership. Asher oversees the company’s operations and resources, guiding major corporate decisions and long-term vision. Prior to founding Wearable Devices, he held engineering and leadership roles at Intel Haifa, specializing in high-speed interface validation. He holds a BSc in Electrical Engineering from Ort Braude College.

Guy Wagner, Chief Scientific Officer and President, co-founded Wearable Devices Ltd. in 2014 and has served on its board since inception. As CSO and President, Guy leads the company’s technological innovation and scientific direction. He is the main inventor behind the company’s core technology and brings multidisciplinary expertise in hardware design, biomedical signal processing, embedded programming, and sensor systems. He previously worked at Intel as a hardware engineer and holds a BSc in Electrical Engineering from Ort Braude College.

Leeor Langer, co-founder and CTO since 2016, is a leading expert in algorithms, machine learning, and signal and image processing. He has held senior R&D roles in the medical imaging and digital security sectors, including at Intel, and brings deep academic and industry experience. Leeor has authored several scientific papers and holds a BSc from the Technion and an MSc in Applied Mathematics from Tel Aviv University, graduating cum laude.

Wearable Devices Ltd. (NASDAQ: WLDS), closed Monday's trading session at $0.73, off by 6.4582%, on 161,025 volume. The average volume for the last 3 months is 158,587 and the stock's 52-week low/high is $0.685/$11.3999.

Recent News

• Wearable Devices Ltd. (NASDAQ: WLDS) - TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) to Debut Mudra Experience Studio at MWC Barcelona 2026
• TechMediaBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Launches ai6 Labs Neural AI Ecosystem to Bridge Human Intent and Digital Reality
• AINewsBreaks - Wearable Devices Ltd. (NASDAQ: WLDS) Featured in AINewsWire Editorial on Next Wave of AI Investment

Olenox Industries Inc. (NASDAQ: OLOX)

The QualityStocks Daily Newsletter would like to spotlight Safe and Green Holdings Corp. (NASDAQ: OLOX).

Olenox Industries Inc. (NASDAQ: OLOX) is a diversified holding company focused on delivering innovative solutions across infrastructure, construction, energy, healthcare, and environmental sectors. Originally established in 2007 as SG Blocks, the company has evolved into a vertically integrated platform serving both public and private sector clients with modular, sustainable systems. Its operations span a range of industries unified by a commitment to efficient, scalable design and sustainability-driven development.

The company’s model centers on the production and deployment of prefabricated modular structures, energy systems, and infrastructure technologies, leveraging vertical integration and cross-sector synergies to support government agencies, medical networks, developers, and commercial enterprises. Safe and Green’s subsidiaries operate collaboratively to generate multiple revenue streams while pursuing opportunities in both traditional and next-generation infrastructure.

Safe and Green Holdings Corp. is headquartered in Miami, Florida.

Portfolio

SG Echo Manufacturing

SG Echo is the modular manufacturing arm of Safe and Green Holdings Corp., delivering prefabricated structures built from steel, wood, and repurposed shipping containers. As a Made-in-America manufacturer, SG Echo combines industry-leading machinery and skilled labor to execute modular projects for clients across the U.S. and globally. The company holds an ESR certification from the International Code Council for repurposed containers, enabling faster approvals and widespread applicability in commercial and industrial construction.

With the ability to reduce construction time by up to 50% and cut costs by 10–20%, SG Echo’s manufacturing process emphasizes speed, sustainability, and resilience. In October 2025, SG Echo’s operations were consolidated into a new facility in Conroe, Texas, where they now operate alongside Olenox Corp., a Safe and Green subsidiary focused on oil and gas operations, to streamline logistics and integrate manufacturing with field operations. Revenue is also generated through third-party property leasing at the Conroe site.

SG Modular Medical

SG Modular Medical designs and deploys modular point-of-care solutions tailored for the evolving demands of healthcare infrastructure. The system enables clinics and labs to be rapidly assembled from clinical, administrative, and diagnostic modules, offering adaptability based on local needs and population shifts. This modular approach is positioned as a lower-emission alternative to traditional medical construction, helping reduce the substantial carbon footprint associated with healthcare infrastructure.

Notable deployments include COVID-19 testing pods at Los Angeles International Airport (LAX), designed and delivered in partnership with airport authorities. Another initiative, launched with The Peoples Healthcare and Teamsters Local 848, involves delivering modular clinics to serve union members with onsite, high-quality care staffed by a top-tier clinical operator.

SG Development Corp.

SG DevCorp is the real estate development division of Safe and Green Holdings Corp., focused on building modular single- and multifamily projects across various income levels. The company pursues strong, green developments supported by vertically integrated manufacturing from SG Echo. SG DevCorp has stated development targets of more than 4,000 modular units totaling over 3.2 million square feet across 1,000+ acres of acquired land—a construction pipeline valued at approximately $765 million.

The division prioritizes sustainability throughout the lifecycle of its developments, reducing construction waste, energy usage, emissions, and noise pollution. Its projects aim to minimize the environmental impact while enhancing speed-to-market and structural resilience.

SG Environmental Solutions

SG Environmental Solutions provides modular environmental infrastructure and sustainable waste management technologies. At the core of this division is Sanitec, a patented system designed for medical waste sterilization and volume reduction. The technology helps organizations reduce their environmental impact while significantly lowering operational costs.

The company emphasizes responsible construction and stewardship through upcycling, waste reduction, and adaptable modular deployments. Its container-based platforms are built for diverse use cases across commercial, residential, industrial, and environmental applications, with a focus on high-efficiency, reduced-emission outcomes.

Olenox Energy

Olenox Energy is the energy development arm of Safe and Green Holdings, focused on acquiring and revitalizing distressed oil and gas assets. In May 2025, the company acquired 1,600 acres of wells and leases from Sherman Oil & Gas and its affiliates, adding 111 wells to the Olenox portfolio. Since the acquisition, Olenox has produced over 3,000 barrels of oil and is currently achieving peak production rates of 55 barrels per day. The company is preparing additional workovers to add 25–30 bpd and has completed full asset mobilization into Texas. Olenox also holds a 51% stake in Winchester Oil & Gas, representing more than 500 wells across the state.

The company is executing its strategy to build a fully integrated oil and gas platform. Olenox operations remain in full compliance with the Texas Railroad Commission, with a stated emphasis on environmental stewardship and reduced lease operating expenses.

In September 2025, Safe and Green entered into an Open Collaborative Framework with OneQode, a global digital infrastructure company. The agreement supports joint development of spill detection, real-time telemetry, and command systems for remote energy assets, enhancing Olenox’s operational capabilities through automation and data infrastructure.

Market Opportunity

Safe and Green Holdings is positioned to capitalize on macro trends across multiple sectors. The construction and real estate industries continue to seek faster, greener alternatives to traditional building methods—needs that SG Echo and SG DevCorp address through prefabricated, modular designs. In healthcare, rising demand for scalable care infrastructure underscores the relevance of SG Modular Medical’s point-of-care solutions.

Within energy, Olenox targets long-term value in revitalizing overlooked oil and gas assets. Its operational model, combined with emerging infrastructure technology partnerships, aims to improve field performance while maintaining environmental compliance. Through this diversification, Safe and Green aligns its platform with infrastructure modernization, energy resilience, and sustainability imperatives.

Leadership Team

Michael McLaren, Chairman and Chief Executive Officer, brings over 30 years of leadership in the energy industry, including military and field service projects, mergers and acquisitions, and technology development. He is the founder of Olenox Ltd., a developer of proprietary energy systems, and holds advanced degrees in Science and Business from the University of British Columbia. McLaren has authored multiple papers on alternative fuels and energy systems and serves as a lead strategist for Safe and Green’s cross-sector growth.

Patricia Kaelin, CPA, Chief Financial Officer, has more than 30 years of experience in public company financial management, mergers and acquisitions, and strategic capital deployment. She previously served as CFO and CIO of a billion-dollar construction company overseeing operations across 14 states. Her background spans construction, healthcare, manufacturing, and real estate. Kaelin holds a bachelor’s degree in business administration with a concentration in accounting from California State University, Fullerton.

Jim Pendergast, Chief Operating Officer, has held executive leadership roles across multiple sectors, including energy, construction, and agriculture. He has served as COO, CFO, and CEO at public and private firms, overseeing operations, acquisitions, and project execution. He holds an MBA in international business and finance from McMaster University and a BA in political studies and economics from Queen’s University.

Olenox Industries Inc. (NASDAQ: OLOX), closed Monday's trading session at $1.63, up 32.5203%, on 30,950,190 volume. The average volume for the last 3 months is 2,543,356 and the stock's 52-week low/high is $0.7928/$96.

Recent News

• Olenox Industries Inc. (NASDAQ: OLOX) - MissionIRNewsBreaks - Olenox Industries (NASDAQ: OLOX) Reports Well Revitalization Success and Near-Term Production Target
• NetworkNewsBreaks - Olenox Industries (NASDAQ: OLOX) Launches 2026 Drilling Program, Targets 1,000 BOE per Day by Year-End
• MissionIRNewsBreaks - Olenox Industries (NASDAQ: OLOX) Subsidiary Selected for Newark Segment of New Jersey Greenway State Park

D-Wave Quantum Inc. (NYSE: QBTS)

The QualityStocks Daily Newsletter would like to spotlight D-Wave Quantum Inc. (NYSE: QBTS).

D-Wave Quantum Inc. (NYSE: QBTS) is a leader in quantum computing systems, software and services focused on delivering customer value via practical quantum applications for problems such as logistics, artificial intelligence, materials sciences, drug discovery, scheduling, fault detection and financial modeling. As the only provider building both annealing and gate-model quantum computers, the company is unlocking commercial use cases in optimization today, while building the technologies that will enable new solutions tomorrow.

D-Wave is a pioneer in quantum computing, with a history of delivering the world’s first commercial quantum computer; the first real-time quantum cloud service; countless hardware and software product and research milestones; and the planned first cross-platform quantum solution which will deliver both annealing and gate-model quantum computers to customers via an integrated platform. Its current commercial product offerings include: Advantage™ (fifth generation quantum computer), Leap™ (quantum cloud service), Launch™ (quantum computing onboarding service) and Ocean™ (full suite of open-source programming tools).

D-Wave’s relentless pursuit of practical quantum computing has resulted in the technology being used today by some of the world’s most advanced enterprises – more than 25 of the Forbes Global 2000 use D-Wave.

D-Wave’s commercial customers include blue-chip industry leaders like Volkswagen, Accenture, BBVA, NEC Corporation, Save-On-Foods, DENSO and Lockheed Martin. The company boasts an extensive IP portfolio featuring more than 200 issued U.S. patents and over 100 peer-reviewed papers published in leading scientific journals.

Founded in 1999, D-Wave is the world’s first commercial supplier of quantum computers. With headquarters and the Quantum Engineering Center of Excellence based near Vancouver, Canada, D-Wave’s U.S. operations are based in Palo Alto, California.

Advantage™ Quantum Computer

 

With the Advantage™ Quantum Computer, D-Wave has incorporated two decades of experience and over 10 years of customer feedback to create the first and only quantum computer designed for business. The platform features a new processor architecture with over 5,000 qubits and 15-way qubit connectivity. This is 2.5x more connections and more than double the number of qubits than the company’s previous generation quantum computer.

D-Wave’s quantum computers, first located in its facilities in British Columbia, have been available to North American users through its Leap™ quantum cloud service since 2018. It has since introduced new Advantage systems in Julich, Germany, and most recently, Marina Del Rey, California, which marked the availability of the first Advantage quantum computer physically located in the United States.

That new deployment is part of the USC-Lockheed Martin Quantum Computing Center (QCC) hosted at USC’s Information Sciences Institute (ISI), a unit of the University of Southern California’s prestigious Viterbi School of Engineering. Additionally, Amazon Web Services (AWS) and D-Wave announced that the U.S.-based system is available for use in Amazon 2racket, expanding the number to three different D-Wave quantum systems available to AWS users.

Leap Quantum Cloud Service

 

D-Wave’s customers interface with its systems through the Leap™ quantum cloud service. Leap delivers immediate, real-time access to the company’s Advantage quantum computer and quantum hybrid solver service, all with enterprise-class performance and scalability.

Leap allows developers proficient in Python to get started building and running quantum applications. Through a seamless and secure cloud-based connection, users can easily start solving complex problems of up to 1 million variables and 100,000 constraints.

Using Leap, D-Wave customers have developed quantum hybrid applications for use cases in manufacturing, logistics, financial services, life sciences, materials science, retail and transportation. By eliminating the need to wait hours, days or weeks to get good answers to a broad array of problems, D-Wave is helping businesses move forward.

D-Wave Launch

D-Wave Launch™ is the company’s onboarding platform aimed at helping businesses easily start their quantum journey. Through this program, D-Wave’s team of experts and partners aid enterprises in identifying best use cases for quantum and work with them to develop a proof of concept and production pilot.

From there, the team coordinates with customers to get their hybrid quantum applications up and running, providing ongoing Leap quantum cloud access to ensure the application is operating smoothly and delivering real business value.

Target Verticals

While the potential applications for quantum computing are effectively limitless, D-Wave has identified a number of industry verticals as key areas of focus for its quantum architecture, providing case studies for each. These include:

• Manufacturing – D-Wave worked with Volkswagen to identify a commercial optimization application, the binary paint shop problem, which was run on D-Wave’s hybrid solver service. The solver outperformed four purely classical methods on problem sizes at commercial scale (N=3,000). In a separate project, similar inputs were tested using a leading ion trap system, which failed to find any commercial solution.
• Life Sciences – Menten AI makes use of D-Wave quantum computing to assist in the design of novel therapeutic peptides—short strings of amino acids that can act as potent drugs. With the rise of COVID-19, D-Wave’s Advantage system made it possible to identify molecules that might be especially well-suited for binding and inhibiting the related spike protein, producing several promising peptide designs.
• Finance – Multiverse Computing, a leader in developing quantum solutions for the financial sector, leveraged D-Wave’s hybrid solver service in a collaboration with BBVA, one of the world’s largest financial institutions. Multiverse demonstrated management strategies that far exceeded the granularity of traditional returns in a fraction of the time, helping BBVA identify a low-risk portfolio for investment.

Market Opportunity

The quantum computing total addressable market is projected to grow between $450 billion and $850 billion over the next 15 to 30 years, with between $5 billion and $10 billion of anticipated TAM growth coming in the next three to five years, according to Boston Consulting Group. Driving factors behind this growth include rising investments in quantum computing tech by governments and an increasing number of commercial use-cases.

Forward-thinking organizations see quantum as an opportunity to move ahead of the competition. From finding efficiencies and reducing waste to decreasing time to solution and solving problems abandoned due to complexity, the business value is real. According to data from 451 Research, 40% of large enterprises are already experimenting with quantum computing.

D-Wave is strategically positioned – in an industry with significant barriers to entry – as evident by a decades-long track record serving a roster of blue-chip customers. The company is singularly focused on helping its customers achieve clear value by leveraging quantum computing in practical business applications. With a full stack of systems, software, developer tools and services, D-Wave is working to enable enterprises, governments, developers and researchers to access the power of quantum computing, thereby providing an intriguing opportunity for prospective investors.

D-Wave’s current investor base includes PSP Investments, Goldman Sachs, BDC Capital, NEC Corporation, Aegis Group Partners and In-Q-Tel.

Leadership Team

Dr. Alan Baratz has served as the CEO of D-Wave since 2020. Previously, as Executive Vice President of R&D and Chief Product Officer, he drove the development, delivery, and support of all of D-Wave’s products, technologies, and applications. Dr. Baratz has over 25 years of experience in product development and bringing new products to market at leading technology companies and software startups. As the first president of JavaSoft at Sun Microsystems, he oversaw the growth and adoption of the Java platform from its infancy to a robust platform supporting mission-critical applications in nearly 80 percent of Fortune 1000 companies. He has also held executive positions at Symphony, Avaya, Cisco, and IBM. Dr. Baratz holds a doctorate in computer science from the Massachusetts Institute of Technology.

John Markovich is the company’s CFO. He brings to D-Wave over three decades of experience working with rapidly growing private and public technology companies across all stages of development. Mr. Markovich has directed the finance, accounting, tax, treasury, M&A, legal, operations, customer service, IR, HR, and IT functions for companies ranging from privately held pre-revenue startups to an NYSE-listed Fortune 500 multi-national company with over $1.2 billion in annual revenue. During his career, he has negotiated and closed over 150 debt, equity, M&A, and joint venture transactions exceeding $2.5 billion in value; over a dozen private placements; nearly a dozen M&A transactions; and several international joint ventures. Mr. Markovich holds a BS in Business from Miami University and an MBA from the Michigan State Graduate School of Business.

D-Wave Quantum Inc. (NYSE: QBTS), closed Monday's trading session at $19.04, up 2.4207%, on 26,090,486 volume. The average volume for the last 3 months is 26,341,988 and the stock's 52-week low/high is $4.49/$46.75.

Recent News

• D-Wave Quantum Inc. (NYSE: QBTS) - Reports Indicate US Military Used Anthropic's AI in Iran Strikes
• Trump Orders Federal Agencies to Stop Using AI Tools from Anthropic
• China Announces Availability of Quantum Computing OS for Public Download

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) s a critical metals technology company developing scalable rare earth element (“REE”) refining infrastructure in North America. Originally founded in 2006 as a mineral exploration company, Ucore has since evolved into a processing technology innovator focused on commercializing its proprietary RapidSX™ platform under a $18.4 million contract from the U.S. Department of Defense, with additional support from Natural Resources Canada. The company’s flagship deployment is the Louisiana Strategic Metals Complex (“SMC”), with additional SMCs planned to follow.

Ucore’s mission is to help reestablish a domestic REE supply chain by offering competitive, modular processing solutions that reduce dependence on China. Supported by government funding, private capital, and engineering partnerships, Ucore aims to meet growing demand for rare earth oxides in electric vehicles, defense systems, and advanced energy technologies.

The company is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Separation Technology

RapidSX™ is Ucore’s proprietary rare earth separation platform, delivering three times faster processing than traditional solvent extraction (SX) methods. Its current demonstration program in Kingston, Ontario, is being conducted under contract with the U.S. Department of Defense to prove commercial readiness for processing both heavy and light REEs. The project is also supported by Natural Resources Canada.

RapidSX™ employs a column-based design that eliminates the need for powered mixer-settlers, enabling a smaller facility footprint, quicker commissioning, and lower CAPEX and OPEX. The platform is adaptable to light and heavy REE feedstocks and is structured for modular scale-up.

The 52-stage RapidSX™ Commercial Demonstration Plant in Kingston, Ontario—operated in partnership with Kingston Process Metallurgy—has logged thousands of runtime hours and is currently processing rare earth feedstock further to the company’s U.S. Department of Defense contract. In January 2025, Ucore secured a $500,000 non-dilutive grant from Ontario’s Critical Minerals Innovation Fund to support the advancement of the Kingston facility and, in the words of Ontario Mines Minister George Pirie, “build a secure supply chain ready to fuel the technologies of tomorrow.”

Strategic Metals Complex – Louisiana

Ucore has selected an 80,800-square-foot brownfield site within the England Airpark in Alexandria, Louisiana, as the location for its first commercial rare earth refining facility. The Louisiana SMC is expected to scale from 2,000 tonnes per annum (TPA) of total rare earth oxides initially to 5,000 TPA, with potential to ultimately reach 7,500 TPA.

The facility benefits from Foreign Trade Zone (FTZ) status, reducing tariff burdens on imported inputs and enhancing logistics efficiency. In addition to these structural advantages, the state of Louisiana has outlined an incentive package valued at $15 million, including a $900,000 infrastructure grant and $360,000 in additional local support. The project is expected to create 100 family-wage jobs and has received strong support from federal and state officials.

To date, Ucore has secured $2.3 million in milestone payments under its $18.4 million OTA award from the U.S. Department of Defense. In early 2024, the company also secured C$2.16 million in private investment from Hondo Private Equity to support its commercialization efforts.

Bokan-Dotson Ridge REE Project – Alaska

Ucore maintains 100% ownership of the Bokan-Dotson Ridge heavy REE project in Southeast Alaska. A Preliminary Economic Assessment was completed in January 2013. The Alaska Industrial Development and Export Authority (AIDEA) has authorized $145 million in bond financing under SB99 (2014) to support future development.

While Bokan remains a long-term asset, Ucore continues to advance it at a measured pace, complementing its near-term focus on commercial rare earth refining and oxide production at the Louisiana SMC.

Market Opportunity

According to Grand View Research, the global rare earth elements market was estimated at $3.95 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2025 to 2030. The market outlook remains strong, fueled by the growing demand for permanent magnets and catalysts in the automotive sector.

In March 2025, President Trump invoked the Defense Production Act to prioritize domestic critical mineral production, signaling a national mandate to reduce reliance on “hostile foreign powers’ mineral production.” One month later, the Chinese government enacted immediate export restrictions on seven key rare earth elements, including dysprosium and terbium, further intensifying pressure on Western nations to develop secure and independent supply chains. This underscores the strategic value of Ucore’s domestic separation infrastructure.

Leadership Team

Pat Ryan, P.Eng., Chairman and CEO, is the founder of Neocon International, a leading automotive OEM supplier. He brings over 25 years of experience in global supply chain innovation and has led Ucore since 2014 in its strategic pivot toward rare earth processing.

Peter Manuel, Vice President, CFO & Corporate Secretary, has served as Ucore’s financial lead for 14 years. Trained as a Chartered Accountant, with extensive experience across Canada, England, and Ireland, Mr. Manuel has advised public and private entities on strategic planning, treasury, and assurance.

Michael Schrider, MEng, P.E., Vice President & COO, is a multidisciplinary engineer with over 30 years of experience. He founded and operated engineering firms SAi and ABD and has overseen all phases of Ucore’s technical development since 2016.

Geoff Atkins, Vice President of Business Development, has 30 years of mining experience and was instrumental in advancing both Lynas’ Mt. Weld and Vital Metals’ Nechalacho REE operations. He brings deep operational knowledge and leads feedstock strategy at Ucore.

Ucore Rare Metals Inc. (OTCQX: UURAF), closed Monday's trading session at $4.79, up 5.0439%, on 2,182,965 volume. The average volume for the last 3 months is 261,640 and the stock's 52-week low/high is $0.515/$10.69.

Recent News

• Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) - EnergyNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Provides Update on Samarium and Gadolinium Supply Initiative
• DefenseNewsBreaks - Ucore Rare Metals Inc. (TSXV: UCU) (OTCQX: UURAF) Highlights Rare Earth Price Surge And Ranks Second On 2026 TSX Venture 50
• MiningNewsBreaks - Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Submits Final Phase 1 Report Under US Department of War OTA